Secondary outcomes include changes in log-transformed NT-proBNP at 52weeks, time to first cardiovascular event (death, HF hospitalization, orworsening HF), adverse event profiles, and pharmacokinetics of tablet and oralsuspension formulations. This evidence concerns the gene NPPB and hydrops fetalis.